Basedow Disease
Conditions
Brief summary
Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).
Interventions
None listed
Sponsors
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients aged 18 and older with moderate to severe orbitopathy; * Patients followed in endocrinology with the goal of achieving euthyroidism; * Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS); * Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy; * Patients with a CAS ≥ 3 or CAS \<3 with moderate to severe orbitopathy (according to EUGOGO); * Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment; * Patients who are not opposed to the reuse of their health data.
Exclusion criteria
* Patients who have undergone bone or fat decompression surgery; * Patients with severe corneal involvement (Grade B or C; NO SPECS classification); * Patients with optic neuropathy (Grade B and C; NO SPECS classification); * Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy; * Patients who have opposed the reuse of their health data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to second-line basedow treatment | Patients who started a second-line treatment between January 2022 and December 2023, with clinical follow-up until the end of 2024, were included in order to minimize selection bias. inclusion period: until december 2025 | Practices in France regarding the use of these second-line treatments appear to be heterogeneous, and their effectiveness has never been compared through randomized studies. investigators propose to collect and analyze the therapeutic outcomes of second-line treatment in patients with Graves' orbitopathy. The data collection concerns patients with Graves' orbitopathy who have received corticosteroid therapy and a second-line treatment (immunosuppressant, biotherapy) since 2022. Data from the medical records of patients included. |
Countries
France
Contacts
Primary ContactBoris BIENVENU, DR
Outcome results
None listed